Ping Zhu, MD, MMed, PhD

Assistant Professor, Department of Neurosurgery

Ping Zhu

Contact Info

Assistant Professor, Department of Neurosurgery


MD, Fudan University, Shanghai, China

PhD in epidemiology, biostatistics, and cancer, The University of Texas Health Science Center at Houston

Master of Medicine in epidemiology and health statistics, Fudan University, Shanghai, China

Summary

Dr. Zhu earned her PhD in epidemiology, biostatistics, and cancer from the University of Texas Health Science Center at Houston, and her MD and Master of Medicine in epidemiology and health statistics from Fudan University in Shanghai, China. Prior to coming to the U, she was a biostatistician at the University of Texas Health Science Center.

Dr. Zhu has a comprehensive background and specific expertise in epidemiology and biostatistics with more than 10 years of research experience, including study design (cross-sectional, cohort, and clinical trial), data management/data cleanup, statistical analysis, and manuscript writing. She has developed more than 11 population-based studies using 6 national-scale datasets as a co-PI and statistician and has collaborated with a multidisciplinary team that included neuro-oncology, neurosurgery, radiology, and pathology in more than 10 clinical research projects. Dr. Zhu’s research interest is to explore the contributors and related impacts on the outcomes of primary brain/central nervous system tumors and brain cancer metastases.

Professional Associations

Society for Neuro-oncology

Research

Publications

Publications

  1. McCormack R, Zhu P (co-1st author), Dono A, Takayasu T, Bhatia A, Blanco A, Tandon N, Ostrom Q, Gonzales A, Moreno S, Ballester L, Esquenazi Y. Impact of Race and Geographic Location on IDH1/2 Mutations and Glioblastoma Survival. World Neurosurgery, 2021 May, 149:e894-e912
  2. Patrizz A, Dono A, Zhu P, Tandon N, Ballester L, Esquenazi Y. Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: Does pathology predict outcomes? Journal of Neuro-Oncology, 152 (1), 163-172
  3. Dono A, Zhu P, Zorofchian S, Takayasu T, Quezado M, Rios A, Powers A, Esquenazi Y, Ballester L. Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. Clinical Neuropathology, DOI: https://doi.org/10.5414/np301287
  4. Tong B, Esquenazi Y, Johnson J, Zhu P, Tandon N. The Brain is Not Flat: Conformal Electrode Arrays Diminish Complications of Subdural Electrode Implantation. World Neurosurgery, in press, DOI: https://doi.org/10.1016/j.wneu.2020.09.063
  5. Rollo P, Rollo M, Zhu P, Woolnough O, Tandon N. The Accuracy and Efficacy of Oblique Trajectories in Robotic Stereoelectroencephalography. Journal of Neurosurgery, Aug 14;1-10. DOI: 10.3171/2020.5.JNS20975
  6. Lopez-Rivera V, Zhu P, Dono A, Lee S, Chen P, Ballester L, Sheth S, Esquenazi Y. Increased Risk of Subsequent Meningioma Among Women with Malignant Breast Cancer. World Neurosurgery, 2020 Apr S1878-8750 (20) 30674-4. DOI: https://doi.org/10.1016/j.wneu.2020.03.203
  7. Zhu P, Esquenazi Y, Du X, Blanco A, Zhu J. Impact of facility type and volume in low-grade glioma outcomes. Journal of Neurosurgery, 2019 Sep 27:1-11. DOI: 10.3171/2019.6.JNS19409
  8. Morris S, Zhu P (co-1st author), Rao M, Martir M, Hsu S, Zhu J, Ballester L, Tandon N, Kim D, Shepard S, Blanco A, Esquenazi Y. Gamma Knife Stereotactic Radiosurgery in Combination with Bevacizumab for Focally Recurrent Glioblastoma. World Neurosurgery, 127, e523-e533, Jul 2019. DOI: 10.1016/j.wneu.2019.03.193
  9. Lu G, Rao M, Zhu P, Liang B, El-Nazer R, Fonkem E, Bhattacharjee M, Zhu J. Triple Chemotherapies with Bevacizumab, Irinotecan and Temozolomide plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. Frontiers Neurology, 10:42. DOI: 10.3389/fneur.2019.00042
  10. Zhu P, Du X, Zhu J, Esquenazi Y. Improved Survival of Glioblastoma Patients Treated at Academic and High-Volume Facilities: A Hospital-Based Study from the National Cancer Database. Journal of Neurosurgery. 2019 Feb 15:1-12. DOI: 10.3171/2018.10.JNS182247
  11. Ballester L, Lu G, Zorofchian S, Vantaku V, Putluri V, Yan Y, Arevalo O, Zhu P, Riascos R, Sreekumar A, Esquenazi Y, Putluri N, Zhu J. Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun. 2018 Aug 31; 6(1):85. DOI: 10.1186/s40478-018-0588-z.
  12. Zhu P, Zhu J. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. Chin Clin Oncol. 2017 Aug;6(4):41. DOI:10.21037/cco.2017.06.29.
  13. Zhu P, Du X, Lu G, Zhu J. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget. 2017 Jul 4;8(27):44015-44031. DOI: 10.18632/oncotarget.17054.

Oral presentations

  1. 25th annual meeting of the Society for Neuro-Oncology (SNO), Austin, Texas, U.S., November2020, Zhu P, Du X, Blanco AI, Ballester LY, Tandon N, Zhu J, Hadjipanayis CG, Berger MS, Esquenazi Y. EPID-34. The detrimental effect of biopsy preceding resection in surgically accessible Glioblastomas:Results from the National Cancer Database. Neuro-Oncology, 22(Supplement_2):ii85-ii86, 10.1093/neuonc/noaa215.352
  2. 96th Annual Meeting of American Association of Neuropathologist, Virtual Meeting. June 2020 Achi HE, Dono A, Zhu P, Bundrant BE, Esquenazi Y, and Ballester LY. Diffuse gliomas with FGFR alterations, histopathological features, genetic alterations, and potential clinical implications.
  3. 24th annual meeting of the SNO, Phoenix, Arizona, U.S., November 2019 Zhu P, Du X, Zhu J. EPID-16. Comparative analysis of Overall Survival and Adverse Events by Adjuvant Treatment Modalities in Elderly Patients with Glioblastoma Using the SEER-Medicare Database. Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi77–vi78, https://doi.org/10.1093/neuonc/noz175.316
  4. 24th annual meeting of the SNO, Phoenix, Arizona, U.S., November 2019 Zorofchian S, Zhu P, Takayasu T, Rios A, Quezado M, Esquenazi Y, Ballester L. PATH-24. CXCR4 is a Potential Therapeutic Target for Glioblastoma and Diffuse Intrinsic Pontine Gliomas. Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi148, https://doi.org/10.1093/neuonc/noz175.620
  5. 71st American Academy of Neurology annual meeting, Philadelphia, U.S., May 2019. Zhu P, Du X, Esquenazi Y, Zhu J. EPID-01. Impact of Travel Distance to Care Facility on Survival in Patients with Glioblastoma: A Retrospective Study Using the National Cancer Database. Neurology, https://n.neurology.org/content/92/15_Supplement/S...
  6. 23rd annual meeting of the SNO, New Orleans, U.S., November 2018. Zhu P, Du X, Esquenazi Y, Zhu J. EPID-01. Associations of timing of adjuvant therapies, radiation fractions and radiation doses with glioblastoma survival: A retrospective cohort analysis using the National Cancer Database and SEER-Medicare database. Neuro-Oncology, 20 (suppl_6): vi80-vi80. DOI: 10.1093/neuonc/noy148.328
  7. 18th Biennial Canadian Neuro-Oncology Meeting, Banff, Canada, May 2018. Zhu P, Du X, Esquenazi Y, Zhu J. 51. Timing of adjuvant treatments on glioblastoma survival: A retrospective cohort analysis based on the National Cancer Database. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 45(S3), S11-S12. doi: https://doi.org/10.1017/cjn.2018.291
  8. 22nd annual meeting of the SNO, San Francisco, U.S., November 2017. Zhu P, Du X, Zhu J, Esquenazi Y. HOUT-12. Improved survival of glioblastoma patients treated at academic cancer programs: A hospital-based study from the National Cancer Database. Neuro-Oncology, Volume 19, Issue suppl_6, Pages vi108, https://doi.org/10.1093/neuonc/nox168.443.

Posters

  1. 25th annual meeting of the SNO, Austin, Texas, U.S., November 2020. Zhu P, Du X, Zhu J. EPID-30. Predictors Associated with Long-term Survivorship for Patients with Glioblastoma using the National Cancer Database (NCDB). Neuro-Oncology, 22(Supplement_2):ii85-ii86,10.1093/neuonc/noaa215.352
  2. 25th annual meeting of the SNO, Austin, Texas, U.S., November 2020. Dono A, Zhu P, Holmes E, Takayasu T, Blanco AI, Hsu Sigmund, Bhattacharjee M, Zhu J, Ballester L, Esquenazi Y, Tandon N. Reoperation in molecular subtypes of recurrent glioblastoma.
  3. Neuro-Oncology American Society of Clinical Oncology (ASCO) annual meeting, Chicago, Illinois, U.S., May 2019. Zhu P, Du X, Esquenazi Y, Zhu J. E13576. Impact of access to clinical trials, multidisciplinary environment, and health care providers on outcomes of patients with newly diagnosed glioblastoma using SEER-Medicare dataset. Journal of Clinical Oncology. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.1...
  4. 24th annual meeting of the SNO, Phoenix, Arizona, U.S., November 2019. McCormack R, Zhu P (co-1st author), Takayasu T, Hines G, Zeineddine H, Tandon N, Jimenez S, Gonzalez A, Ballester L, Esquenazi Y. EPID-12. Impact of Race and Geographic Location on IDH Mutations and Glioblastoma Survival. Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi76–vi77, https://doi.org/10.1093/neuonc/noz175.312
  5. Congress of Neurological Surgeons (CNS) Annual meeting, Houston, U.S., October 2018. Morris SA, Zhu P (co-1st author), Esquenazi Y. Gamma Knife Stereotactic Radiosurgery and Bevacizumab can be safely used to prolong survival for focally recurrent Glioblastoma.
  6. Congress of Neurological Surgeons, 2018 Annual meeting. CNS Tumors: Tumor Section Satellite Symposium, Houston, U.S., October 2018. Zhu P, Du X, Esquenazi Y, Zhu J. Improved Survival in Patients with Low-Grade Glioma Undergoing Treatment at Academic and High-Volume Facilities. CNS Tumors: 2018 Tumor Section Satellite Symposium.
  7. 22nd annual meeting of the SNO, San Francisco, U.S., November 2017. Zhu P, Du X, Lu G, Zhu J. EPID-02. Survival benefit of glioblastoma patients after FDA approval of bevacizumab, a population-based study using SEER, TCR, and NCDB databases, Neuro-Oncology, Volume 19, Issue suppl_6, 6 November 2017, Pages vi69, https://doi.org/10.1093/neuonc/nox168.280
  8. 22nd annual meeting of the SNO, San Francisco, U.S., November 2017. Lu G, Zhu P, Shao R, Zhu J. PATH-31. Elevation of YKL-40, normalized to ceruloplasmin, in cerebrospinal fluid is associated with glioblastoma recurrence. Neuro-Oncology, Volume 19, Issue suppl_6, 6 November 2017, Pages vi177, https://doi.org/10.1093/neuonc/nox168.721
  9. 5th World Federation of Neuro-Oncology Societies (WFNOS) Meeting, Zurich, Switzerland, May 2017. Lu G, Rao M, Zhu P, Tian X, Linendoll N, Pilichowska M, Glass WF, Hunter R, Zhu J. P09.63. Postmortem evaluation of end-organ toxicity in patients with glioblastoma treated with temozolomide, bevacizumab and irinotecan. Neuro-Oncology, Volume 19, Issue suppl_3, 1 May 2017, Pages iii84, https://doi.org/10.1093/neuonc/nox036.318.